middle.news
Can Cynata’s 2026 Trial Results Transform Its Fortunes Amid $9.39M Loss?
3:01am on Saturday 30th of August, 2025 AEST
•
Healthcare
Read Story
Can Cynata’s 2026 Trial Results Transform Its Fortunes Amid $9.39M Loss?
3:01am on Saturday 30th of August, 2025 AEST
Key Points
Net loss narrowed slightly to $9.39 million in FY2025
Revenues declined 22.7% to $2.11 million
Phase 1 diabetic foot ulcer trial completed with positive safety and efficacy data
Three clinical trials (aGvHD, osteoarthritis, kidney transplant) progressing with results due in 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cynata Therapeutics (ASX:CYP)
OPEN ARTICLE